↓ Skip to main content

Dove Medical Press

Article Metrics

New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine

Overview of attention for article published in Therapeutics and Clinical Risk Management, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
7 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
46 Mendeley
Title
New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine
Published in
Therapeutics and Clinical Risk Management, November 2015
DOI 10.2147/tcrm.s64915
Pubmed ID
Authors

Rafael Coveñas, Felix-Martin Werner

Abstract

Cariprazine is a recently developed antipsychotic drug with a partial agonism for the D2 and D3 receptors. It shows a tenfold greater affinity for the D3 receptor. In clinical trials, its therapeutic effect has been tested in patients with an acute exacerbation of schizophrenia and in patients with acute mania in bipolar disorder. Like risperidone, cariprazine improves positive and negative schizophrenic symptoms, and ameliorates cognitive functions. Cariprazine induces extrapyramidal symptoms less often than risperidone and can cause acute akathisia. It is a prolactin-sparing antipsychotic drug and has a favorable metabolic profile. In acute mania in bipolar disorder, it treats manic symptoms significantly better than placebo. As a consequence of its improved adverse effects, cariprazine improves patients' quality of life to a greater extent than other second-generation antipsychotic drugs. Cariprazine is a promising antipsychotic drug in the treatment of schizophrenia, acute mania in bipolar disorder, and in schizophrenia with mania. In these patients, its long-term therapeutic effect and its action in comparison with other second-generation antipsychotic drugs, above all aripiprazole, remain to be tested in clinical trials.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 2%
Unknown 45 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 26%
Student > Ph. D. Student 5 11%
Student > Doctoral Student 5 11%
Student > Master 5 11%
Other 4 9%
Other 9 20%
Unknown 6 13%
Readers by discipline Count As %
Medicine and Dentistry 15 33%
Psychology 10 22%
Agricultural and Biological Sciences 3 7%
Nursing and Health Professions 2 4%
Neuroscience 2 4%
Other 7 15%
Unknown 7 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2018.
All research outputs
#4,609,917
of 22,831,537 outputs
Outputs from Therapeutics and Clinical Risk Management
#227
of 1,264 outputs
Outputs of similar age
#63,718
of 284,444 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#8
of 54 outputs
Altmetric has tracked 22,831,537 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,264 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,444 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.